Previous Close | 85.88 |
Open | 85.83 |
Bid | 85.21 x 800 |
Ask | 85.22 x 900 |
Day's Range | 84.87 - 85.86 |
52 Week Range | 57.55 - 86.60 |
Volume | |
Avg. Volume | 695,509 |
Market Cap | 8.587B |
Beta (5Y Monthly) | 0.83 |
PE Ratio (TTM) | 22.33 |
EPS (TTM) | 3.82 |
Earnings Date | Jul 30, 2024 - Aug 05, 2024 |
Forward Dividend & Yield | 0.60 (0.70%) |
Ex-Dividend Date | Jul 01, 2024 |
1y Target Est | 95.30 |
Penumbra's (PEN) Thrombectomy product category shows encouraging growth trends, reflecting strong momentum in CAVT products.
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and PNTG are well-poised to gain.
Veracyte's (VCYT) first-quarter 2024 performance reflects the strength of its testing business.